Mirabella Financial Services LLP Buys Shares of 29,914 Bristol-Myers Squibb (NYSE:BMY)

Mirabella Financial Services LLP acquired a new position in Bristol-Myers Squibb (NYSE:BMY - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 29,914 shares of the biopharmaceutical company's stock, valued at approximately $1,692,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Fairway Wealth LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $28,000. Comprehensive Financial Planning Inc. PA purchased a new stake in Bristol-Myers Squibb during the 4th quarter worth about $34,000. Westend Capital Management LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $38,000. Tacita Capital Inc purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $39,000. Finally, M Holdings Securities Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $39,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock traded down $0.83 during midday trading on Friday, hitting $47.86. The company had a trading volume of 16,290,683 shares, compared to its average volume of 13,089,597. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The company's 50 day simple moving average is $56.50 and its 200 day simple moving average is $56.50. The stock has a market cap of $97.38 billion, a price-to-earnings ratio of -10.83, a PEG ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.25. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. During the same period in the previous year, the company posted ($4.40) EPS. Research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.18%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's payout ratio is -56.11%.

Analyst Ratings Changes

BMY has been the subject of a number of recent research reports. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday. Piper Sandler began coverage on Bristol-Myers Squibb in a report on Tuesday. They issued an "overweight" rating and a $65.00 price objective on the stock. Finally, Jefferies Financial Group lowered their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $58.00.

Insider Buying and Selling

In other news, EVP Samit Hirawat acquired 1,823 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average price of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.09% of the stock is owned by company insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.